Relmada Therapeutics Inc. Publishes Mid-Year 2025 Shareholder Letter

Reuters09-10

Relmada <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Publishes Mid-Year 2025 Shareholder Letter

Relmada Therapeutics Inc. issued a mid-year letter to shareholders, signed by Chief Executive Officer Sergio Traversa. The letter provides an update on the company's progress and outlines recent strategic developments. A comprehensive strategic review led to the addition of two Phase 2 product candidates: NDV-01, for non-muscle invasive bladder cancer, and Sepranolone, for compulsivity disorders such as Prader-Willi Syndrome. Six-month follow-up data from the Phase 2 study of NDV-01 showed a 91% complete response rate. Preparations are underway to initiate a Phase 3 trial in the first half of 2026. The letter also discusses upcoming activities related to Sepranolone, including FDA engagement and manufacturing activities planned for the second half of 2025, and the initiation of a Phase 2 study in the first half of 2026. The full letter can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-086389), on September 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2566609112?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 20:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566609112","market":"us","top_or_hot":-1,"title":"Relmada Therapeutics Inc. Publishes Mid-Year 2025 Shareholder Letter","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Publishes Mid-Year 2025 Shareholder Letter\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Relmada Therapeutics Inc. issued a mid-year letter to shareholders, signed by Chief Executive Officer Sergio Traversa. The letter provides an update on the company's progress and outlines recent strategic developments. A comprehensive strategic review led to the addition of two Phase 2 product candidates: NDV-01, for non-muscle invasive bladder cancer, and Sepranolone, for compulsivity disorders such as Prader-Willi Syndrome. Six-month follow-up data from the Phase 2 study of NDV-01 showed a 91% complete response rate. Preparations are underway to initiate a Phase 3 trial in the first half of 2026. The letter also discusses upcoming activities related to Sepranolone, including FDA engagement and manufacturing activities planned for the second half of 2025, and the initiation of a Phase 2 study in the first half of 2026. The full letter can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-086389), on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Relmada Therapeutics Inc. Publishes Mid-Year 2025 Shareholder Letter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelmada Therapeutics Inc. Publishes Mid-Year 2025 Shareholder Letter\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-10 20:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Publishes Mid-Year 2025 Shareholder Letter\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Relmada Therapeutics Inc. issued a mid-year letter to shareholders, signed by Chief Executive Officer Sergio Traversa. The letter provides an update on the company's progress and outlines recent strategic developments. A comprehensive strategic review led to the addition of two Phase 2 product candidates: NDV-01, for non-muscle invasive bladder cancer, and Sepranolone, for compulsivity disorders such as Prader-Willi Syndrome. Six-month follow-up data from the Phase 2 study of NDV-01 showed a 91% complete response rate. Preparations are underway to initiate a Phase 3 trial in the first half of 2026. The letter also discusses upcoming activities related to Sepranolone, including FDA engagement and manufacturing activities planned for the second half of 2025, and the initiation of a Phase 2 study in the first half of 2026. The full letter can be accessed through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-086389), on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RLMD","symbol_name":"Relmada Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL5xGxnF:1","article_id":"2566609112","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566609112","pubTimestamp":1757508408,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Relmada Therapeutics Inc. issued a mid-year letter to shareholders, signed by Chief Executive Officer Sergio Traversa. The letter provides an update on the company's progress and outlines recent strategic developments. A comprehensive strategic review led to the addition of two Phase 2 product candidates: NDV-01, for non-muscle invasive bladder cancer, and Sepranolone, for compulsivity disorders such as Prader-Willi Syndrome. Six-month follow-up data from the Phase 2 study of NDV-01 showed a 91% complete response rate. Preparations are underway to initiate a Phase 3 trial in the first half of 2026. The letter also discusses upcoming activities related to Sepranolone, including FDA engagement and manufacturing activities planned for the second half of 2025, and the initiation of a Phase 2 study in the first half of 2026. The full letter can be accessed through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RLMD":"Relmada Therapeutics, Inc.","BK4007":"制药"},"translate_title":"Relmada Therapeutics Inc.发布2025年年中股东信","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLMD":0.9},"content_text":"Relmada Therapeutics Inc. Publishes Mid-Year 2025 Shareholder Letter\n    \n\n        Relmada Therapeutics Inc. issued a mid-year letter to shareholders, signed by Chief Executive Officer Sergio Traversa. The letter provides an update on the company's progress and outlines recent strategic developments. A comprehensive strategic review led to the addition of two Phase 2 product candidates: NDV-01, for non-muscle invasive bladder cancer, and Sepranolone, for compulsivity disorders such as Prader-Willi Syndrome. Six-month follow-up data from the Phase 2 study of NDV-01 showed a 91% complete response rate. Preparations are underway to initiate a Phase 3 trial in the first half of 2026. The letter also discusses upcoming activities related to Sepranolone, including FDA engagement and manufacturing activities planned for the second half of 2025, and the initiation of a Phase 2 study in the first half of 2026. The full letter can be accessed through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relmada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-086389), on September 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566609112","isCrawlerRequest":true}